All Clinical Trials

A listing of 23143 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Trials

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Research Study

Recruiting

Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Sinusitis

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Featured Trial

Depressive disorder Clinical Study

Recruiting

A clinical study for people that suffer with Depressive disorder

Conditions:

Depressive disorder

Learn More

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

NCT06976216

Recruiting

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease

Gender:

ALL

Ages:

Between 60 years and 85 years

Trial Updated:

07/31/2025

Locations: Local Institution - 0173, Long Beach, California +111 locations

Local Institution - 0173, Long Beach, California

Local Institution - 0008, Redlands, California

Local Institution - 0025, Basalt, Colorado

Local Institution - 0024, Washington, District of Columbia

Local Institution - 0154, Atlantis, Florida

Local Institution - 0128, Aventura, Florida

Local Institution - 0023, Merritt Island, Florida

Local Institution - 0055, Ocala, Florida

Local Institution - 0263, Stuart, Florida

Local Institution - 0184, The Villages, Florida

Local Institution - 0016, Columbus, Georgia

Center for Advanced Research & Education, Gainesville, Georgia

Local Institution - 0109, Chicago, Illinois

Local Institution - 0054, Elk Grove Village, Illinois

Boston Center for Memory, Newton, Massachusetts

Local Institution - 0110, Saint Paul, Minnesota

Local Institution - 0123, Toms River, New Jersey

Local Institution - 0101, New York, New York

Local Institution - 0259, New York, New York

Local Institution - 0202, Syracuse, New York

Local Institution - 0007, Charlotte, North Carolina

Local Institution - 0073, Columbus, Ohio

Local Institution - 0026, Dayton, Ohio

Local Institution - 0067, Portland, Oregon

Local Institution - 0004, Abington, Pennsylvania

Local Institution - 0056, East Providence, Rhode Island

Local Institution - 0099, Cordova, Tennessee

Local Institution - 0152, Knoxville, Tennessee

Local Institution - 0018, Beaumont, Texas

Local Institution - 0088, Banfield, Buenos Aires

Local Institution - 0001, Buenos Aires, Ciudad Autonoma De Buenos Aires

Local Institution - 0271, Buenos Aires, Not set

Local Institution - 0228, Córdoba, Not set

Local Institution - 0232, Córdoba, Not set

Local Institution - 0085, Córdoba, Not set

Local Institution - 0279, Kogarah, New South Wales

Local Institution - 0245, Macquarie Park, New South Wales

Local Institution - 0244, Sydney, New South Wales

Local Institution - 0242, Carlton, Victoria

Local Institution - 0243, Perth, Western Australia

Local Institution - 0168, Brasília, Distrito Federal

Local Institution - 0180, Curitiba, Paraná

Local Institution - 0266, Aracaju, Sergipe

Local Institution - 0165, São Paulo, Not set

Local Institution - 0233, Kelowna, British Columbia

Local Institution - 0234, Richmond, British Columbia

Local Institution - 0236, Halifax, Nova Scotia

Local Institution - 0237, Ottawa, Ontario

Local Institution - 0235, Toronto, Ontario

Local Institution - 0238, Greenfield Park, Quebec

Local Institution - 0239, Victoriaville, Quebec

Local Institution - 0264, Quebec, Not set

Local Institution - 0230, Antofagasta, AN

Local Institution - 0272, Providencia, Región Metropolitana De Santiago

Local Institution - 0094, Santiago, Región Metropolitana De Santiago

Local Institution - 0089, Santiago, Región Metropolitana De Santiago

Local Institution - 0241, Santiago, Región Metropolitana De Santiago

Local Institution - 0215, Zagreb, Grad Zagreb

Local Institution - 0284, Zagreb, Grad Zagreb

Local Institution - 0216, Osijek, Not set

Local Institution - 0267, Rijeka, Not set

Local Institution - 0240, Zagreb, Not set

Local Institution - 0227, Brno, Brno-město

Local Institution - 0225, Olomouc, Olomoucký Kraj

Local Institution - 0221, Plzen, Plzeň-město

Local Institution - 0223, Prague, Praha 6

Local Institution - 0224, Praha, Praha 6

Local Institution - 0222, Praha, Praha 8

Local Institution - 0226, Rychnov nad Kněžnou, Not set

Local Institution - 0217, München, Bayern

Local Institution - 0219, Münster, Nordrhein-Westfalen

Local Institution - 0276, Mainz, Rheinland-Pfalz

Local Institution - 0218, Berlin, Not set

Local Institution - 0277, Bremen, Not set

Local Institution - 0275, Hamburg, Not set

Local Institution - 0256, Athens, Attikí

Local Institution - 0274, Athens, Attikí

Local Institution - 0251, Thessaloniki, Thessaloníki

Local Institution - 0257, Larissa, Thessalía

Local Institution - 0281, Alexandroupolis, Not set

Local Institution - 0288, Bengaluru, Karnataka

Local Institution - 0282, Hyderabad, Telangana

Local Institution - 0285, Hyderabad, Telangana

Local Institution - 0287, Varanasi, Uttar Pradesh

Local Institution - 0286, Kolkata, West Bengal

Local Institution - 0249, Milano, Lombardia

Local Institution - 0246, Milano, Lombardia

Local Institution - 0248, Monza, Lombardia

Local Institution - 0247, Brescia, Not set

Local Institution - 0209, Gwangju-si, Kwangju-Kwangyǒkshi

Local Institution - 0214, Seongnam, Kyǒnggi-do

Local Institution - 0211, Gangseo-gu, Seoul-teukbyeolsi [Seoul]

Local Institution - 0213, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0208, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0210, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0212, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0261, Torun, Kujawsko-pomorskie

Local Institution - 0280, Bialystok, Podlaskie

Local Institution - 0260, Gdansk, Pomorskie

Local Institution - 0262, Poznań, Wielkopolskie

Local Institution - 0181, San Juan, Not set

Local Institution - 0278, Bucharest, București

Local Institution - 0269, Bucharest, București

Local Institution - 0270, Bucharest, București

Local Institution - 0273, Bucharest, București

Local Institution - 0268, Iași, Not set

Local Institution - 0255, Seville, Andalucía

Local Institution - 0254, Sant Cugat del Vallès, Barcelona [Barcelona]

Local Institution - 0258, Barcelona, Catalunya [Cataluña]

Local Institution - 0253, Lleida, Lleida [Lérida]

Local Institution - 0252, Pamplona, Navarra

Local Institution - 0250, Madrid, Not set

Conditions: Alzheimer's Disease

Learn More ›

Motivational Interviewing to Increase Uptake of Drug Checking and Safe Drug Use Behaviors to Reduce Overdose

NCT06855836

Recruiting

A hybrid type 1 study will be conducted to evaluate efficacy and preliminary implementation considerations for a novel intervention to promote uptake of drug checking services (DCS) and safer drug use behaviors among people who use drugs (PWUD) to reduce incidence of overdose (OD) and HIV and Hepatitis C virus (HCV) infections in San Diego County. Along with \~50 other syringe services programs (SSPs) in the US, the Harm Reduction Coalition San Diego (HRCSD), a local SSP, recently launched Chec... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/31/2025

Locations: MI CHANCE - Park Blvd, San Diego, California

Conditions: Overdose

Learn More ›

Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidiasis

NCT07109869

Recruiting

This is a Phase 3 clinical study to evaluate the efficacy, safety, and tolerability of boric acid 600 mg vaginal inserts in patients with VVC.

Gender:

FEMALE

Ages:

12 years and above

Trial Updated:

07/31/2025

Locations: Alliance for Multispecialty Research - Mobile, Mobile, Alabama +19 locations

Conditions: Vulvovaginal Candidiases, Vulvovaginal Candidiasis, Genital, Vulvovaginal Candidiasis (VVC)

Learn More ›

Virtual Reality-Integrated Propulsion Feedback for Stroke Rehab

NCT07087743

Recruiting

This study evaluates a novel Virtual Reality (VR)-integrated visual feedback system designed to enhance limb propulsion during robot-assisted gait rehabilitation in individuals post-stroke. In collaboration with CUREXO, a rehabilitation robotics company, the system is embedded within the Morning Walk® end-effector robot and provides real-time visual feedback to facilitate symmetrical use of the paretic and non-paretic limbs. The goal is to address gait asymmetry commonly observed in hemiparetic... Read More

Gender:

ALL

Ages:

20 years and above

Trial Updated:

07/31/2025

Locations: University of Texas Medical Branch, Galveston, Texas

Conditions: Stroke, Robot Assisted Gait Training, Virtual Reality

Learn More ›

Prescription Opioids, Brain Structure, and Cognition in Older Adults With Chronic Pain

NCT06837857

Recruiting

The purpose of this study is to determine whether exposure to prescription opioids is associated with brain structural changes on magnetic resonance imaging (MRI), with the primary outcome of white matter integrity as measured by fractional anisotropy of the corpus callosum.

Gender:

ALL

Ages:

65 years and above

Trial Updated:

07/31/2025

Locations: Mayo Clinic in Rochester, Rochester, Minnesota

Conditions: Pain, Chronic

Learn More ›

A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV

NCT06812494

Recruiting

HVTN 206/HPTN 114 is a randomized, double blind, controlled, phase 2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and neutralization of VRC07-523LS, PGT121.414.LS, and PGDM1400LS broadly neutralizing monoclonal antibodies given intravenously in adult participants without HIV. The hypothesis of the study is that the combination of VRC07-523LS and PGT121.414.LS and PGDM1400LS antibodies when administered via the intravenous (IV) route will be safe and tolerable in adult... Read More

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

07/31/2025

Locations: Bridge HIV, San Francisco Department of Public Health, San Francisco, California +14 locations

Conditions: HIV

Learn More ›

Exploring How to Adapt an Evidence-Based Mindful Self-Compassion Program for Young Adults With Li-Fraumeni Syndrome

NCT07032922

Recruiting

Background: Li-Fraumeni syndrome (LFS) is a genetic disorder that increases the risk of cancer. People who have LFS are 24 times more likely to develop cancer than those who do not. Past research studies have shown that living with high cancer risk can cause distress in young adults with LFS. Mindful self-compassion (MSC) is a therapeutic resource that has helped people with and without cancer cope with distress and other mental health challenges. Researchers at the National Cancer Institute (N... Read More

Gender:

ALL

Ages:

Between 18 years and 29 years

Trial Updated:

07/31/2025

Locations: NCI Shady Grove Campus, Rockville, Maryland

Conditions: Li-Fraumeni Syndrome

Learn More ›

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT06859008

Recruiting

This phase I trial tests zanubrutinib in combination with sonrotoclax for treating underrepresented ethnic and racial minorities with B-cell non-Hodgkin lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Many racial and ethnic minorities face additional treatment challenges which may lead to poorer outcomes, however, there are fewer racial and ethnic minorities participating in clinical trials. Zanubrutinib, a type o... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/31/2025

Locations: City of Hope Medical Center, Duarte, California

Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Splenic Marginal Zone Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Nodal Marginal Zone Lymphoma, Refractory Splenic Marginal Zone Lymphoma

Learn More ›

Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004

NCT06813781

Recruiting

This is a Phase I, multicentre, single-dose, non-randomised, open-label, parallel-group study to examine the PK, safety, and tolerability of AZD5004 in male and female participants with mild, moderate, and severe hepatic impairment compared with participants with normal hepatic function.

Gender:

ALL

Ages:

Between 18 years and 80 years

Trial Updated:

07/31/2025

Locations: Research Site, Lake Forest, California +4 locations

Conditions: Hepatic Impairment

Learn More ›

A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

NCT06833008

Recruiting

The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new study drug IPN01195 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places, including cancers in organs or tissues that have spread from their original site to nearby tissues or other parts of the body.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/31/2025

Locations: START Mid-West, Grand Rapids, Michigan +12 locations

Conditions: Advanced Solid Tumor

Learn More ›

A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine

NCT07010471

Recruiting

A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants with Developmental and Epileptic Encephalopathies Followed by an Open-Label Extension

Gender:

ALL

Ages:

Between 2 years and 65 years

Trial Updated:

07/31/2025

Locations: Praxis Research Site, Chevy Chase, Maryland

Conditions: Developmental and Epileptic Encephalopathy 1

Learn More ›

Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06960395

Recruiting

This Phase 1, first-in-human (FIH), dose-escalation and dose-expansion study is designed to evaluate the safety, PK, and preliminary anti-tumor activity of VIR-5525 as a monotherapy and in combination with pembrolizumab in participants with solid tumors that are known to express EGFR. The study will be conducted in the following 4 parts: * Part 1: VIR-5525 monotherapy dose escalation * Part 2: VIR-5525 monotherapy dose expansion * Part 3: VIR-5525 plus pembrolizumab dose escalation * Part 4: V... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/31/2025

Locations: Honor Health Research Institute, Scottsdale, Arizona +2 locations

Conditions: Solid Tumor Malignancies, EGFR Positive Solid Tumors, EGFR

Learn More ›